Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
– Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December – – CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies – – $342 million in cash, cash equivalents & marketable securities, as of June … [Read more…]
